Breaking News, Financial News

Financial Report: Abbott 1Q11

Pharmaceutical sales were $3.8 billion in the quarter, up 12%. Humira sales were up 18% to $1.6 billion.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Abbott 1Q11 1Q Revenues: $9.0 billion (+17%) 1Q Earnings: $864.0 million (-14%) Comments: Pharmaceutical sales were $3.8 billion in the quarter, up 12%. Humira sales were up 18% to $1.6 billion. Trilipix/TriCor sales were $372 million, up 28%. Kaletra sales dropped 15% to $248 million. Niaspan sales were up 11% to $226 million. Synthroid sales were $145 million, up 18%. R&D expenses were up 27% to $930 million. Medical device sales were $1.2 billion (+11%). Earnings were impacted by...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters